Figure 3.
Heparin alleviates SARS-CoV-2 infection in diabetic models
A, B: Body weight changes (A) and blood glucose levels (B) in hACE2-Lepr-/- and hACE2-Lepr+/+ mice infected by 1×104 TCID50 of SARS-CoV-2 and treated with low-dose (1 mg/kg) and high-dose (5 mg/kg) heparin. C: SARS-CoV-2 N gene and sub-gene levels were detected using qPCR in the lungs of hACE2-Lepr-/- and hACE2-Lepr+/+ mice treated with drugs. D: IHC assay for SARS-CoV-2 N proteins in lungs of hACE2-Lepr-/- and hACE2-Lepr+/+ mice treated with heparin. 5×, scale bar represents 400 µm; 20×, scale bar represents 100 µm. E: Lung pathological (H&E) scores (left) were counted according to INHAND standard rules, and SARS-CoV-2 N protein-positive area (right) was calculated using Case Viewer. F: Histopathological changes in lung tissues of hACE2-Lepr-/- and hACE2-Lepr+/+ mice treated with drugs (arrow indicates inflammatory cell infiltration, bold arrow indicates hyaline membrane). 5×, scale bar represents 200 µm; 20×, scale bar represents 50 µm.